(Washington / Beijing Comprehensive News) China National Medical Security Bureau said that the negotiations with Pfizer Pharmaceutical Company's negotiations on the treatment of crown diseases failed to succeed, and Pfizer's crown oral drug Paxlovid failed to be included in the medical insurance directory.
Comprehensive Bloomberg and Surging News reported that the four -day China National Medical Insurance Catalog was negotiated on Sunday (January 8).The person in charge of the Medical Management Department of the National Medical Insurance Bureau said that there are three types of crown disease therapy drugs that have been negotiated this time.China's domestic crown disease oral drugs Azf fixed tablet, lung detoxification particles have been negotiated successfully.
According to the previous notice of the National Medical Insurance Bureau of China, the three drugs negotiated this time have been temporarily incorporated into the scope of medical insurance payment. Before March 31st, PAXLOVID can still enjoy relevant medical insurance reimbursement policies in China.
As the earliest batch of crown -taking oral drugs in the world, PAXLOVID, the prices of medical insurance in China were originally 2300 yuan (RMB, the same below, about S $ 451), which has recently dropped to 1890 yuan.However, as a "star drug", it is not easy to buy Paxlovid in China. Many hospitals said that the drug inventory is tight, and in unofficial channels, a box of PaxLovid prices are as high as tens of thousands of yuan.
Pfizer continues to cooperate with Chinese to ensure that PaxLovid is sufficient
Pfizer said on Monday that although the negotiations with relevant countries were not successful, Pfizer will continue to cooperate with the government and other stakeholders to ensure that PaxLovid's sufficient supply in China.
Reuters reported on Saturday that the Chinese government is still negotiating with Pfizer's permission agreement to allow domestic companies to produce PaxLovid's generic drugs.According to the agreement reached with the Geneva Pharmaceutical Penalty Pond, five Chinese companies have been authorized to be PAXLOVID generic drugs with low production prices in low -income countries, but they cannot sell products in China.
